May 14, 2020 / 1:39 PM / 17 days ago

BRIEF-Krystal Biotech Says Phase 2 Study In 4-6 Pediatric Patients Anticipated To Start In H2 2020

May 14 (Reuters) - Krystal Biotech Inc:

* KRYSTAL BIOTECH ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 1/2 CLINICAL TRIAL OF KB105 IN PATIENTS WITH TGM1-RELATED AUTOSOMAL RECESSIVE CONGENITAL ICHTHYOSIS (ARCI)

* KRYSTAL BIOTECH INC - KB105 WAS WELL TOLERATED WITH NO ADVERSE EVENTS OR IMMUNE RESPONSE FOLLOWING REDOSING

* KRYSTAL BIOTECH INC - PHASE 2 STUDY IN 4-6 PEDIATRIC PATIENTS ANTICIPATED TO INITIATE IN SECOND HALF OF 2020

* KRYSTAL BIOTECH INC - PHENOTYPIC EVALUATION OF KB105 TREATED AREAS SHOWED REDUCED REVERSION TO ICHTHYOTIC SCALING PHENOTYPE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below